Vanguard Capital Management Files 13G, Discloses 6.5% Stake in Moderna

Vanguard Capital Management LLC, the investment arm of the world’s largest index provider, reported holding 25,933,824 shares of Moderna, representing 6.53% of the company’s outstanding common stock. The filing, submitted under Rule 13d‑1(b) as a passive institutional disclosure, indicates that Vanguard does not intend to influence Moderna’s management or board composition.

The filing aggregates holdings across Vanguard’s network of affiliates—including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers LLC, and Vanguard Investments Australia Ltd.—and covers securities over which Vanguard exercises dispositive power, as well as client securities where it holds voting authority. Vanguard’s sole voting power is limited to 3,061,366 shares, while it retains sole dispositive power over the full 25.9 million shares.

For shareholders, the disclosure is a signal that a major passive investor views Moderna’s trajectory favorably. The stock is currently trading at $46.22, up 1.10% on the day and 55.0% year‑to‑date, with a Relative Strength Index of 35, suggesting the shares remain in oversold territory despite the rally. Moderna’s market capitalization sits at $18.3 billion, and the stock is positioned at roughly 63% of its 52‑week range, indicating room for upside.

While the 13G filing does not bring any activist agenda, the size of Vanguard’s stake—well above the 5% threshold that triggers public reporting—adds a layer of credibility to Moderna’s recent clinical and commercial milestones. Investors will watch whether Vanguard’s passive endorsement translates into broader index fund inflows, potentially bolstering liquidity and supporting the stock’s upward momentum.

The filing is an initial Schedule 13G and not an amendment, meaning Vanguard’s stake is newly disclosed rather than a change to a prior filing.